Press release - 17/11/2026 When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel Julius Michel, a postdoctoral researcher at the German Cancer Research Center, has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology - awarded for the first time and accompanied by a $10,000 prize - as well as another award from the society.https://www.gesundheitsindustrie-bw.de/en/article/press-release/when-brake-cells-become-killer-cells-double-honor-dkfz-researcher-julius-michel
Press release - 12/11/2026 DKFZ Sets Records for ERC Synergy Grants A historic success for the German Cancer Research Center (DKFZ): Four DKFZ researchers are receiving one of the prestigious ERC Synergy Grants this year—more than ever before at a single institution in a single funding round. Three of the four international research consortia are coordinated by the DKFZ. In total, the projects will receive approximately 44.5 million euros, of which about 13.7 million euros will go to the DKFZ.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-sets-records-erc-synergy-grants
Press release - 09/11/2026 Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award Mirco Julian Friedrich, a physician and cancer researcher at the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Research Institute, and Heidelberg University Hospital (UKHD), is being honored for his outstanding research on the aging immune system and the immune response to blood cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mirco-friedrich-receives-peter-and-traudl-engelhorn-foundation-award
Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-guardian-inhibits-aggressive-brain-tumors-ability-switch-between-identities
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 15/10/2026 Four Million Euros in EU Funding to Improve Prostate Cancer Care A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient.https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-million-euros-eu-funding-improve-prostate-cancer-care
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer-1
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer
Press release - 08/09/2026 Quality Over Quantity: New Insights into the Role of Specific CAR T Cells in Cancer Therapy CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-over-quantity-new-insights-role-specific-car-t-cells-cancer-therapy
Press release - 08/09/2026 Heisenberg Professorship for Aurélie Ernst With funding from the German Research Foundation’s (DFG) Heisenberg Program, DKFZ researcher Aurélie Ernst aims to investigate how massive changes in the genome contribute to the development of cancer. Her research focuses on a phenomenon known as chromothripsis - a catastrophic event in the genome in which chromosomes break apart and are reassembled incorrectly.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heisenberg-professorship-aurelie-ernst
Press release - 03/09/2026 Triple ERC Success at the German Cancer Research Center Three researchers at the German Cancer Research Center (DKFZ) have each been awarded a Starting Grant from the European Research Council (ERC) this year. Daniel Kirschenbaum, Lena Kutscher, and Michael Scherer impressed the ERC with their innovative research approaches to fundamental questions in cancer medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/triple-erc-success-german-cancer-research-center
Press release - 13/08/2026 PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prame-specific-t-cell-therapy-adolescent-metastatic-kidney-tumor
Press release - 10/08/2026 Immune Cells in Bone Marrow Cancer: Limited Defense Readiness A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
Press release - 05/08/2026 Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium.https://www.gesundheitsindustrie-bw.de/en/article/press-release/center-excellence-oncology-nct-heidelberg-and-mannheim-cancer-center-receive-joint-funding
Press release - 31/07/2026 New insights into Malaria research: How molecular tethers and Asynchronous replication drive parasite proliferation Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-malaria-research-how-molecular-tethers-and-asynchronous-replication-drive-parasite-proliferation
Press release - 22/07/2026 The Individual Genetic Background Shapes the Evolution of Cancer Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/individual-genetic-background-shapes-evolution-cancer
Press release - 20/07/2026 Blood vessels guide immune cells to metastases It has long been suspected that endothelial cells play a key role in determining how the body’s immune system responds to tumors. Researchers at the DKFZ and the Medical Faculty Mannheim of Heidelberg University have now identified, in mouse studies, a specialized population of blood vessel lining endothelial cells that enable an effective immune defense against cancer metastases in the liver. https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-guide-immune-cells-metastases
Press release - 16/07/2026 New Findings on Acute Leukemias: Specific Mutations Provide Targets for More Targeted Therapies Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-acute-leukemias-specific-mutations-provide-targets-more-targeted-therapies
Press release - 16/07/2026 Impact of Overweight on Cancer Risk May Be Significantly Underestimated Being overweight and obesity may contribute to significantly more cancer cases than previously thought. This is the conclusion reached by researchers at the German Cancer Research Center (DKFZ). Their analysis shows that when more accurate measures of body fat and methodological biases are considered, more than 10 percent of all cancer cases can be attributed to increased body weight - nearly twice as many as previous estimates suggested.https://www.gesundheitsindustrie-bw.de/en/article/press-release/impact-overweight-cancer-risk-may-be-significantly-underestimated
Press release - 09/07/2026 DKFZ Innovation Award and DKFZ Patient Expert Award Presented The Friends of the German Cancer Research Center (DKFZ) support the DKFZ and aim to help strengthen its position in the international arena. With the DKFZ Innovation Award, presented at this year’s annual reception, the association honors Helmut Salih, a researcher whose innovative work bridges the gap between immunological research and patient care.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-innovation-award-and-dkfz-patient-expert-award-presented
Press release - 06/07/2026 New AI System Provides Treatment Recommendations for Complex Blood Cancers Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ai-system-provides-treatment-recommendations-complex-blood-cancers
Press release - 03/07/2026 Vaccine Against Brain Tumors Shows Promising Long-Term Results A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccine-against-brain-tumors-shows-promising-long-term-results
Press release - 02/07/2026 How Tumors Evade Immunotherapy - and How to Prevent It Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-tumors-evade-immunotherapy-and-how-prevent-it
Press release - 02/07/2026 Virus influences rare brain lymphomas Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/virus-influences-rare-brain-lymphomas
Press release - 01/07/2026 Double ERC Success for DKFZ Researchers Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.https://www.gesundheitsindustrie-bw.de/en/article/press-release/double-erc-success-dkfz-researchers